Is there a risk of melanoma with erectile dysfunction drugs?

Last Updated on

November 01, 2017 – According to the watch list of the American Food & Drug Administration (FDA) for drugs with possible safety issues from January to March 2016,

the FDA was looking at the possible link between various drugs in the phosphodiesterase-5 (PDE-5) inhibitors class and melanoma as a serious adverse effect. Drugs in this class include Sildenafil (Viagra), Tadalafil (Cialis), Vardenafil (Levitra), Vardenafil (Staxyn), and Avanafil (Stendra), all for the indication of erectile dysfunction. Moreover, Tadalafil (Cialis) is also prescribed sometimes when doctors see the signs and symptoms of benign prostatic hyperplasia (BPH). Likewise, two other PDE-5 inhibitors, Sildenafil (Revatio) and Tadalafil (Adcirca) are FDA-approved for the treatment of pulmonary arterial hypertension (PAH).

To date, there has not been any status update from the FDA on their investigation about this possible malignant melanoma adverse effect of these PDE-5 drugs. But during 2017 thus far, there have been a few medical journal articles published regarding the safety issue of whether PDE-5 inhibitor drugs might cause or promote skin cancer, especially melanoma, which can be fatal.

The latest review article on the issue appeared online in the journal Sexual Medicine Reviews on October 12, 2017 and was entitled “Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction”. From this article’s abstract, there are two relevant points presented by these medical researchers:

  • There appears to be an association between Phosphodiesterase type 5 (PDE-5) inhibitor use and melanoma but the absence of a mechanism of causation raises doubt that the association is cause and effect.
  • Evidence on increased rates of melanoma and prostate cancer recurrence is weak and controversial.

 

A second article was published online in the Oncotarget Journal in April 2017, entitled in start with “Relation of phosphodiesterase type 5 inhibitors and malignant melanoma: a meta-analysis and systematic review”. The abstract of this article, which sets forth the findings of some medical researchers in China, states that:

Data on the association between using PDE5 inhibitors and malignant melanoma are conflicting. To estimate the relation of using PDE5 inhibitors with risk of malignant melanoma, Medline (Ovid) and Embase (Ovid) databases were searched up to February 2017, and a random effects model was used to calculate the summary risk estimates. Five observational studies were included. Five studies reports encompassed a total of 15,979 melanoma cases occurring among 1, 188,414 participants. The pooled multivariable-adjusted RR of melanoma in patients with using PDE5 inhibitors was 1.12 (95% CI: 1.03–1.21, I2 = 0.48). Findings from this systematic review support that PDE5 inhibitor use is associated with increased risk of melanoma in ED patients, the result remains inclusive and warrants further study in the future.

Lastly, the article  “Phosphodiesterase type 5 inhibitors and risk of melanoma: A meta-analysis”, written by researchers affiliated with American and Chinese medical institutions and published by the Journal of the American Academy of Dermatology in September 2017 states that:

Five observational studies were included. Compared with PDE-5 inhibitor nonuse, PDE-5 inhibitor use was slightly but significantly associated with an increased risk for development of melanoma (OR, 1.12; 95% CI, 1.03-1.21) and basal cell carcinoma (OR, 1.14; 95% CI, 1.09-1.19) but not squamous cell carcinoma. For melanoma risk, none of the prespecified factors (dose of PDE5 inhibitor, study design, and study region) significantly affected the results (P > .05). Our sensitivity analysis confirmed the stability of the results. The conclusion was that use of PDE-5 inhibitors may be associated with a slightly increased risk for development of melanoma and basal cell carcinoma but not squamous cell carcinoma. However, further large well-conducted prospective studies with adequate adjustment for potential confounders are required for confirmation.

Indeed, judging from these investigations, it is no surprise that an association of a risk of melanoma with erectile dysfunction drug use remains controversial. And it comes with no surprise that we still look forward to eventually hearing from the FDA concerning their investigations of this important drug safety issue. Nevertheless, the issue leaves patients who take these drugs with considerable uncertainty.

____________

Tags: , , , , , , , , , , , , , , ,
About the Author
Joseph Gut - thasso Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Your opinion

Comment

No comments yet

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Sickle cell anemia is an inherited form of anemia February 28, 2020
    It's important to know the the symptoms, causes, and treatment of sickle cell anemia, an inherited blood disorder that, in the United States, is more common among African Americans.
  • Scientists discover three genes associated with fatal lung disease February 28, 2020
    Researchers at the Universities of Leicester and Nottingham have discovered parts of the DNA that put some people at higher risk of an incurable lung disease called idiopathic pulmonary fibrosis (IPF). The findings are published in the American Journal of Respiratory and Critical Care Medicine today, after an earlier version was posted online in November […]
  • An understudied cause of cancer: Mutations in regulators of cell signaling February 28, 2020
    Mutations in a vital class of regulatory molecules are an underappreciated cause of cancer because they impair the function of "G" proteins, a versatile and vast family of signaling switches that underlie innumerable biological facets of life itself.
  • Could new discovery play a role in diagnosing Alzheimer's earlier? February 27, 2020
    Scientists have detected that a previously overlooked gene behavior could potentially lead to a new way to diagnose Alzheimer's earlier.
  • Huntington's disease-causing DNA repeat mutations reversed in the lab February 27, 2020
    Neurodegenerative diseases, like Huntington's disease and myotonic dystrophy, are often referred to as DNA repeat diseases, named because of long repeated sequences in the DNA of patients. Increasing repeat expansion length in the affected tissues contribute to earlier age of disease onset and worsen the progression and severity of the disease over time.
  • Researchers announce progress in developing an accurate, noninvasive urine test for prostate cancer February 28, 2020
    Researchers at the Johns Hopkins Kimmel Cancer Center have made significant progress toward development of a simple, noninvasive liquid biopsy test that detects prostate cancer from RNA and other specific metabolic chemicals in the urine.
  • Anomalies in structure of polyvalent metal melts explained February 28, 2020
    Metals and their alloys are the main structural materials of modern civilization. The properties of metal melts are well studied. However, according to Anatoly Mokshin, one of the co-authors of the publication, Chair of the Department of Computational Physics at Kazan Federal University, for more than 25 years, scientists from all over the world have […]
  • New platform for engineering ribosomes to 'cook new cuisines' February 28, 2020
    Researchers have created a method for cell-free synthesis and evolution of new ribosomes that can specialize in the synthesis of functional materials and therapeutics.
  • Cartilage cells, chromosomes and DNA preserved in 75-million-year-old baby duck-billed dinosaur February 28, 2020
    In a paper published online in National Science Review, an international team of scientists present evidence of fossilized cell nuclei and chromosomes within preserved cartilage in a baby duck-billed dinosaur. This dinosaur belongs to Hypacrosaurus and comes from a nesting ground discovered in 1988 by paleontologist Jack Horner in Late Cretaceous sediments of Northwest Montana.
  • Gene therapy generates new neurons to treat Huntington's disease February 28, 2020
    Huntington's disease (HD) is a rare disease with chorea movement and caused by Huntingtin (Htt) gene mutation and neurodegeneration. A research group led by Dr. Gong Chen has developed a novel gene therapy to regenerate functional new neurons in mouse models of HD. The work has been published in Nature Communications on February 27, 2020.
Top